MedTrace Logo

Belatacept in Renal Transplantation: Analyses Using Data From the Collaborative Transplant Study

NCT01471223 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 89

Last updated 2017-09-19

No results posted yet for this study

Summary

The purpose of the study is to estimate the incidence rates of Post-transplant Lymphoproliferative Disorder (PTLD), malignancy and hospitalized infections in adult kidney-only transplant recipients treated with Belatacept, and compared the incidences to the incidences in those treated with Calcineurin inhibitor (CNI) based regimens at the time of transplantation.

Conditions

  • Kidney Transplantation

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2017-08-08
Completion
2017-08-08

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01471223 on ClinicalTrials.gov